All News

Conversations about the financial realities of genomic testing are not always taking place, according to a new study by the American Cancer Society.

The FDA approved a biosimilar to pegfilgrastim, called LA-EP2006 to decrease the incidence of infection, exhibited from febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer therapy that is associated with a clinically significant incidence of febrile neutropenia.

A new machine-learning computer model helped predict which patients of cancer may die soon.

The MEK inhibitor selumetinib showed clinical responses in the plexiform neurofibromas of adult patients with neurofibromatosis type 1.

A look at the latest lung cancer research, recent advances in the field and their clinical applications.

Jennifer Crombie, MD, discusses classification of diffuse large B-cell lymphoma (DLBCL) into distinct subtypes and treatment decisions based on molecular classifications. 

Dr. Allison W. Kurian discusses a new breast cancer study that analyzed the mutations present in breast tumors, and about emerging targeted therapy options.

Immune checkpoint inhibitors have demonstrated impressive activity in patients with CRC and other solid tumors that are dMMR. Researchers explore the data. 

This year has seen many advances in immunotherapy. Here is a look at some of the most significant research. 

Metastasis-directed therapy with stereotactic ablative radiotherapy has emerged as a promising complementary technique for the management of low-volume metastatic prostate cancer.

Personality disorders become exacerbated under stressful cancer-related situations and may lead to adverse consequences and outcomes.

Conversion of tryptophan to kynurenine was associated with lower survival rates.

Immunotherapy responses may not be equal between the sexes.

The approval comes one day after the FDA approved niraparib for the same subset of ovarian cancer.

Alcohol has been labeled a carcinogen by a growing number of agencies across the globe, after years of scientific and policy debate. But just how much of the cancer burden is it responsible for?

Niraparib was approved by the (FDA) for previously treated advanced ovarian, fallopian, or primary peritoneal cancers.

For the first time, researchers have isolated a subtype of gamma-delta T-cells that offers protection in women with triple-negative breast cancer.

Researchers recently looked at differences in survival time between patients with grade II and grade III spinal meningioma.

A new combination may help with overall and progression-free survival in liver cancer.

Why are geriatric patients less likely to get treated for their non-melanoma skin cancers? Researchers investigate and report. 

The agency is set to make a decision on the investigational antibody drug conjugate by the first quarter of 2020.

Researchers explore the predictive capability of EVI1 expression.

Researchers report on the BRIGHT AML 1019 Phase III trial.

A study showed patients seem to lack an understanding of the meaning of progression-free survival.

A pooled analysis of safety, efficacy of pembrolizumab in patients 75+ years of age with PD-L1+ NSCLC

The neoantigens found in the patients’ tumors (non-small-cell lung cancer) which were highly dissimilar were enriched for hydrophobic sequences, and correlated with survival rates after the PD-1 checkpoint therapy.

Researchers examine patterns of recurrence after resection of pancreatic ductal adenocarcinoma.  

Following administration of checkpoint inhibitor therapy, 2.6% of patients experienced an acute vascular event within 6 months of starting treatment.

A study found an association between treatment with ibrutinib and an increased risk for death from toxicities.